Regulation of renal calbindin expression during cisplatin-induced kidney injury.
acute kidney injury
calbindin
cisplatin
kidney injury molecule
nephrotoxicity
Journal
Journal of biochemical and molecular toxicology
ISSN: 1099-0461
Titre abrégé: J Biochem Mol Toxicol
Pays: United States
ID NLM: 9717231
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
revised:
20
11
2021
received:
15
08
2021
accepted:
04
01
2022
pubmed:
12
4
2022
medline:
20
7
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Since the discovery of calbindin release into the urine during renal injury, there has been growing interest in the utility of this protein as a biomarker of nephrotoxicity. However, little is known about the intrarenal regulation of the release and expression of this calcium-regulating protein during kidney injury. We sought to characterize the time-dependent expression and excretion of the protein calbindin in the distal tubule in comparison to kidney injury molecule-1 (Kim-1), a protein in the proximal tubule, in mice treated with cisplatin. Urine, blood, and kidneys were collected from male C57BL/6 mice treated with vehicle or cisplatin (20 mg/kg ip). Urinary concentrations of calbindin and Kim-1 were elevated by 11.6-fold and 2.5-fold, respectively, within 2 days after cisplatin. Circulating creatinine and blood urea nitrogen levels increased in cisplatin-treated mice by 3 days, confirming the development of acute kidney injury. Time-dependent decreases in intrarenal calbindin protein were observed on Days 3 and 4 and a 200-fold upregulation of calbindin (CALB1) and KIM-1 messenger RNAs (mRNAs) was observed on Day 3. These data suggest that early loss of calbindin protein into the urine along with declines in renal calbindin levels initiates a compensatory induction of mRNA expression at later time points (Days 3 and 4). Understanding the regulation of calbindin during cisplatin nephrotoxicity further enhances its utility as a potential urinary biomarker of kidney damage. The results of the current study support the combined use of a proximal (Kim-1) and distal tubule (calbindin) marker to phenotype acute kidney injury secondary to cisplatin administration.
Identifiants
pubmed: 35403300
doi: 10.1002/jbt.23068
pmc: PMC9296602
mid: NIHMS1793909
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
Calbindins
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23068Subventions
Organisme : NIEHS NIH HHS
ID : ES007148
Pays : United States
Organisme : NCI NIH HHS
ID : CA046934
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM123330
Pays : United States
Organisme : NIEHS NIH HHS
ID : ES005022
Pays : United States
Organisme : NIDDK NIH HHS
ID : DK093903
Pays : United States
Organisme : NIGMS NIH HHS
ID : GM123330
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007148
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK093903
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES005022
Pays : United States
Organisme : NCI NIH HHS
ID : CA072720
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Kidney Int. 2010 Apr;77(7):601-8
pubmed: 20090667
FASEB J. 2002 Sep;16(11):1398-406
pubmed: 12205031
Mol Endocrinol. 1995 Mar;9(3):319-26
pubmed: 7776978
Curr Opin Nephrol Hypertens. 2000 Jul;9(4):341-7
pubmed: 10926169
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5850-5
pubmed: 15809430
Anticancer Drugs. 2006 Feb;17(2):207-15
pubmed: 16428940
EMBO J. 2006 Jul 12;25(13):2978-88
pubmed: 16763551
Clin Exp Nephrol. 2014 Jun;18(3):432-43
pubmed: 23864347
Biochim Biophys Acta. 2012 Aug;1820(8):1195-204
pubmed: 22001612
Exp Toxicol Pathol. 2012 Nov;64(7-8):797-805
pubmed: 21377848
Mol Biosyst. 2016 Jan;12(1):133-44
pubmed: 26566257
Am J Pathol. 2014 May;184(5):1299-308
pubmed: 24641901
Kidney Int. 2004 Feb;65(2):531-9
pubmed: 14717923
J Biol Chem. 1986 Dec 25;261(36):16943-7
pubmed: 3023374
Toxicol Appl Pharmacol. 2017 Dec 1;336:66-74
pubmed: 29051111
Exp Biol Med (Maywood). 2018 Feb;243(3):272-282
pubmed: 29231123
Int J Mol Sci. 2017 Jun 22;18(7):
pubmed: 28640195
Urol Int. 1996;56(3):174-9
pubmed: 8860739
Am J Nephrol. 2005 Sep-Oct;25(5):491-9
pubmed: 16155358
J Am Soc Nephrol. 2005 Nov;16(11):3188-95
pubmed: 16148038
J Biol Chem. 1971 May 10;246(9):2808-14
pubmed: 4325081
Toxicol Lett. 2013 Mar 13;217(3):235-42
pubmed: 23287709
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2984-8
pubmed: 8464915
Kidney Int. 2005 Oct;68(4):1708-21
pubmed: 16164647
Toxicol Rep. 2020 Apr 22;7:571-576
pubmed: 32382514
J Biol Chem. 2000 Aug 25;275(34):26328-32
pubmed: 10835428
J Biol Chem. 1989 Oct 15;264(29):17454-61
pubmed: 2551904
Mol Endocrinol. 1989 Mar;3(3):495-502
pubmed: 2747655
Clin Pharmacol Ther. 2017 Apr;101(4):510-518
pubmed: 28002630
J Nutr Sci Vitaminol (Tokyo). 1978;24(3):331-4
pubmed: 211210
Vet J. 2012 Jul;193(1):287-9
pubmed: 22088561
Cancer Biomark. 2005;1(1):59-67
pubmed: 17192032
Toxicology. 2010 Nov 9;277(1-3):49-58
pubmed: 20816719
Am J Physiol. 1982 Dec;243(6):E483-8
pubmed: 7149019
Biochemistry. 2000 Jun 13;39(23):6864-73
pubmed: 10841767
Nat Rev Nephrol. 2009 Aug;5(8):441-9
pubmed: 19546862
J Biol Chem. 2002 May 10;277(19):16662-72
pubmed: 11872749
J Cell Biochem. 1997 Jun 1;65(3):340-8
pubmed: 9138090
Biomarkers. 2011 Nov;16(7):553-66
pubmed: 21955166